Kotb, ShadyDetappe, AlexandreLux, FrançoisAppaix, FlorenceBarbier, Emmanuel L.Tran, Vu-LongPlissonneau, MarieGehan, HélèneLefranc, FlorenceRodriguez-Lafrasse, ClaireVerry, CamilleBerbeco, RossTillement, OlivierSancey, Lucie2016-03-012016Kotb, S., A. Detappe, F. Lux, F. Appaix, E. L. Barbier, V. Tran, M. Plissonneau, et al. 2016. “Gadolinium-Based Nanoparticles and Radiation Therapy for Multiple Brain Melanoma Metastases: Proof of Concept before Phase I Trial.” Theranostics 6 (3): 418-427. doi:10.7150/thno.14018. http://dx.doi.org/10.7150/thno.14018.1838-7640http://nrs.harvard.edu/urn-3:HUL.InstRepos:25658385Nanoparticles containing high-Z elements are known to boost the efficacy of radiation therapy. Gadolinium (Gd) is particularly attractive because this element is also a positive contrast agent for MRI, which allows for the simultaneous use of imaging to guide the irradiation and to delineate the tumor. In this study, we used the Gd-based nanoparticles, AGuIX®. After intravenous injection into animals bearing B16F10 tumors, some nanoparticles remained inside the tumor cells for more than 24 hours, indicating that a single administration of nanoparticles might be sufficient for several irradiations. Combining AGuIX® with radiation therapy increases tumor cell death, and improves the life spans of animals bearing multiple brain melanoma metastases. These results provide preclinical proof-of-concept for a phase I clinical trial.en-USAGuIXradiosensitizerradiation therapybrain metastasesnanoparticlesimaged-guided therapypersonalized medicineJournal Article2016-03-0110.7150/thno.14018